Hutchmed completes enrollment of SAFFRON Phase 3 trial of Orpathys+Tagrisso

Hutchmed (HCM) “announces the completion of patient enrollment of SAFFRON, a global Phase III study of ORPATHYS and TAGRISSO for the treatment of patients with epidermal growth factor receptor (“EGFR”)-mutated, MET-overexpressed and/or amplified, locally advanced or metastatic non-small cell lung cancer, NSCLC, following progression on treatment with TAGRISSO(R). The last patient was randomized on October 31, 2025. This combination represents a promising, chemotherapy-free, all-oral treatment option following progression on an EGFR tyrosine kinase inhibitor, and was granted approval in China in June 2025 based on the results of the SACHI randomized Phase III trial. ORPATHYS is an oral, potent and highly selective MET TKI being jointly developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca. TAGRISSO is a third-generation, irreversible EGFR TKI.”